ATE451914T1 - Dispergierbare bosertan-tablette - Google Patents

Dispergierbare bosertan-tablette

Info

Publication number
ATE451914T1
ATE451914T1 AT06744942T AT06744942T ATE451914T1 AT E451914 T1 ATE451914 T1 AT E451914T1 AT 06744942 T AT06744942 T AT 06744942T AT 06744942 T AT06744942 T AT 06744942T AT E451914 T1 ATE451914 T1 AT E451914T1
Authority
AT
Austria
Prior art keywords
dispersible
bosertan
tablet
pyrimidin
benzenesulfonamide
Prior art date
Application number
AT06744942T
Other languages
English (en)
Inventor
Lovelace Holman
Timm Trenktrog
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37431647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE451914(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Application granted granted Critical
Publication of ATE451914T1 publication Critical patent/ATE451914T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06744942T 2005-05-17 2006-05-15 Dispergierbare bosertan-tablette ATE451914T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2005005367 2005-05-17
PCT/IB2006/051519 WO2006123285A2 (en) 2005-05-17 2006-05-15 Dispersible bosertan tablet

Publications (1)

Publication Number Publication Date
ATE451914T1 true ATE451914T1 (de) 2010-01-15

Family

ID=37431647

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06744942T ATE451914T1 (de) 2005-05-17 2006-05-15 Dispergierbare bosertan-tablette

Country Status (23)

Country Link
US (3) US7959945B2 (de)
EP (1) EP1883397B1 (de)
JP (1) JP4219399B2 (de)
KR (2) KR20100093105A (de)
CN (1) CN101175484B (de)
AT (1) ATE451914T1 (de)
AU (1) AU2006248593B2 (de)
BR (1) BRPI0610187B8 (de)
CA (1) CA2607098C (de)
CY (1) CY1110610T1 (de)
DE (1) DE602006011150D1 (de)
DK (1) DK1883397T3 (de)
ES (1) ES2336943T3 (de)
IL (1) IL187383A (de)
MX (1) MX2007014454A (de)
NO (1) NO339781B1 (de)
NZ (1) NZ564167A (de)
PL (1) PL1883397T3 (de)
PT (1) PT1883397E (de)
RU (2) RU2404774C2 (de)
SI (1) SI1883397T1 (de)
WO (1) WO2006123285A2 (de)
ZA (1) ZA200710903B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007014454A (es) * 2005-05-17 2008-02-07 Actelion Pharmaceuticals Ltd Tableta de bosentan dispersable.
US8664390B2 (en) 2007-06-29 2014-03-04 Generics (Uk) Limited Process for the introduction of hydroxyethoxy side chain in bosentan
JP5683276B2 (ja) 2008-02-08 2015-03-11 ジェネリクス・［ユーケー］・リミテッド ボセンタンの製造方法
WO2010061210A1 (en) 2008-11-03 2010-06-03 Generics [Uk] Limited Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
DK2468281T3 (en) 2009-08-19 2016-03-21 Eisai R&D Man Co Ltd Quinolinderivatholdig pharmaceutical composition
JP5850576B2 (ja) * 2010-07-06 2016-02-03 富士化学工業株式会社 ボセンタン固体分散体
CN102114005B (zh) * 2010-12-06 2012-12-12 武汉武药科技有限公司 一种波生坦胶囊及其制备方法
WO2012139736A1 (en) 2011-04-11 2012-10-18 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Pharmaceutical composition comprising bosentan
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
WO2013169082A1 (ko) 2012-05-11 2013-11-14 한올바이오파마 주식회사 보센탄 제어방출성 경구제제
KR101451327B1 (ko) * 2013-01-08 2014-11-03 안국약품 주식회사 보센탄의 제어방출성 다층 정제 및 그 제조방법
RU2559424C1 (ru) * 2014-06-18 2015-08-10 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения Российской Федерации (ФГБУ "РКНПК" Минздрава России) Способ подбора лекарственной терапии больным с идиопатической легочной гипертензией
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
CN104840965B (zh) * 2015-05-05 2018-05-08 重庆华邦制药有限公司 波生坦的制剂及其稳定剂
KR20160141045A (ko) 2015-05-27 2016-12-08 한올바이오파마주식회사 보센탄을 함유한 약학적 조성물
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
EP3624800A4 (de) 2017-05-16 2021-02-17 Eisai R&D Management Co., Ltd. Behandlung von leberzellkarzinom
CN108703956A (zh) * 2018-08-21 2018-10-26 天津双硕医药科技有限公司 一种含有波生坦的固体药物组合物
WO2021126884A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-pEF)
TR2021019265A2 (tr) * 2021-12-07 2023-06-21 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Bosentan farmasötik bileşimleri.
WO2023128902A1 (en) * 2021-12-30 2023-07-06 Pharmactive Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions comprising bosentan and relevant excipients
EP4456897A4 (de) 2021-12-31 2025-12-10 Tenax Therapeutics Inc Orale formulierungen von levosimendan zur behandlung von pulmonaler hypertonie mit herzinsuffizienz mit konservierter auswurffraktion
CN114533738A (zh) * 2022-02-19 2022-05-27 苏州海景医药科技有限公司 一种波生坦固体药物组合物及其制备方法
WO2026007874A1 (zh) * 2024-07-02 2026-01-08 亚宝药业集团股份有限公司 一种波生坦微片

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
CA2355411A1 (en) * 2000-08-18 2002-02-18 Queen's University At Kingston Combination therapy using sympathetic nervous system antagonists and endothelin antagonists
MXPA04011865A (es) * 2002-05-31 2005-03-31 Schering Corp Polimorfos inhibidores de xantina fosfodiesterasa v.
CA2412856A1 (en) * 2002-11-27 2004-05-27 Frederic Bodin Pharmaceutical composition for the treatment of pulmonary arterial hypertension
KR100604034B1 (ko) 2003-10-08 2006-07-24 주식회사유한양행 암로디핀 유리염기를 함유한 구강 속붕해정 및 그의 조성물
MX2007014454A (es) 2005-05-17 2008-02-07 Actelion Pharmaceuticals Ltd Tableta de bosentan dispersable.

Also Published As

Publication number Publication date
US8309126B2 (en) 2012-11-13
ES2336943T3 (es) 2010-04-19
EP1883397B1 (de) 2009-12-16
AU2006248593B2 (en) 2011-03-17
BRPI0610187B8 (pt) 2021-05-25
NZ564167A (en) 2009-12-24
DE602006011150D1 (de) 2010-01-28
JP4219399B2 (ja) 2009-02-04
EP1883397A2 (de) 2008-02-06
ZA200710903B (en) 2008-12-31
SI1883397T1 (sl) 2010-04-30
BRPI0610187A2 (pt) 2010-06-01
US20080193528A1 (en) 2008-08-14
HK1120212A1 (en) 2009-03-27
CN101175484B (zh) 2012-02-01
KR20080014002A (ko) 2008-02-13
BRPI0610187B1 (pt) 2020-03-03
RU2007146395A (ru) 2009-06-27
US20110245281A1 (en) 2011-10-06
CA2607098C (en) 2012-04-10
MX2007014454A (es) 2008-02-07
WO2006123285A2 (en) 2006-11-23
CY1110610T1 (el) 2015-04-29
DK1883397T3 (da) 2010-04-06
NO339781B1 (no) 2017-01-30
US20130023547A1 (en) 2013-01-24
JP2008540512A (ja) 2008-11-20
RU2010129460A (ru) 2012-01-27
PT1883397E (pt) 2010-02-23
AU2006248593A1 (en) 2006-11-23
IL187383A0 (en) 2008-02-09
CN101175484A (zh) 2008-05-07
US7959945B2 (en) 2011-06-14
KR20100093105A (ko) 2010-08-24
RU2404774C2 (ru) 2010-11-27
PL1883397T3 (pl) 2010-05-31
NO20076325L (no) 2008-02-04
WO2006123285A3 (en) 2007-07-05
CA2607098A1 (en) 2006-11-23
IL187383A (en) 2011-09-27

Similar Documents

Publication Publication Date Title
ZA200710903B (en) Dispersible bosertan tablet
UY29500A1 (es) Proceso quimico
ATE500232T1 (de) Kristalline form von 2-chlor-5-ä3,6-dihydro-3- methyl-2,6-dioxo-4-(trifluormethyl)-1-(2h)- pyrimidinylü-4-fluor-n-äämethyl-(1- methylethyl)aminoüsulfonylübenzamid
ATE482953T1 (de) Hiv-inhibierende 5-(hydroxymethylen- und aminomethylen) substituierte pyrimidine
DE602004032321D1 (de) Die hiv-replikation inhibierende indan-substituierte pyrimidine
CL2011003022A1 (es) Compuestos derivados de 2,4 diaminopirimidina, inhibidores de quinasa ptk2; composicion farmaceutica que comprende a uno de los compuestos, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva, tal como cancer.
MX2009005363A (es) Pirimidinas y su uso como antagonistas del receptor cxcr2.
HRP20041177B1 (hr) Mikrobicidni pirimidini ili triazini za prevenciju prijenosa hiv seksualnim putem
MX2008012576A (es) Pirimidinas 5-amido sustituidas inhibidoras del virus de inmunodeficiencia humana.
WO2007027238A3 (en) Jak kinase inhibitors and their uses
NO2014029I2 (no) Sofosbuvir. (S)-isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropyrimidin-1(2H)-yl)-4-fluor-3-hydroksy-4-metyltetrahydrofuran-2-yl)metoksy)-(fenoksy)fosforylamino)propanoat
EA201070410A1 (ru) Твердые формы (s)-этил-2-амино-3-(4-(2-амино-6-((r)-1-(4-хлор-2-(3-метил-1h-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропаноата и способы их применения
EA201200565A1 (ru) ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА
ATE520672T1 (de) Hiv-hemmende 5-carbo- oder heterozyklisch substituierte pyrimidine
IL181056A0 (en) Hiv inhibiting 5-substituted pyrimidines
WO2008144223A3 (en) Triazolyl aminopyrimidine compounds
TN2010000070A1 (en) Fused bicyclic pyrimidines
GB0502482D0 (en) Novel compounds
UY34191A (es) ?N-(6-((2R,3S)-3,4-Dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilazetidina-1-sulfonamida y sales farmacéuticamente aceptables de lamisma?.
ZA201002214B (en) 3-methyl-2-((2s)-2-(4-(3-methyl-l,2,4-0xadiazol-5-yl)phenyl)morpholino)-6-(pyrimidin-4-yl)pyrimidin-4(3h)-one as tau protein kinase inhibitor
ATE420646T1 (de) Aminopyrimidine als kinase-modulatoren
TR201903012T4 (tr) Bosentan monohidratın ve bunun ara ürünlerinin hazırlanması için proses.
MX2011005611A (es) Sintesis y formas de sales novedosas de (r)-5-((e)-2-(pirrolidin-3 -il-vinil)pirimidina.
ATE350370T1 (de) 2-substituierte pyrimidine
WO2008144222A3 (en) Triazolyl aminopyrimidine compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1883397

Country of ref document: EP